Table 3—

Mean ESRD-related cost and cost-savings per patient (in U.S. dollars)

Follow-up (years)Losartan (n = 751)Placebo (n = 762)Difference95% CIP
2.03,9564,878922−541 to 2,3860.217
2.56,5098,5602,051−23 to 4,1250.053
3.09,45712,9313,474758 to 6,1900.012
3.512,71417,8585,1441,701 to 8,5860.003
4.016,25323,3117,0582,632 to 11,4840.002